Time-Limited G-Ba Resolutions – A Tool To Appropriately Manage Reimbursement Of Innovative Therapies Receiving Expedited Regulatory Approval

October 4, 2018 Danielle Twigg

Since 2011, new pharmacological therapies in Germany are subject to an early benefit assessment (EBA) upon launch by the Federal Joint Committee (G-BA). If a newly approved drug is not deemed to offer an additional benefit over available therapies by the G-BA, it is not granted premium-pricing, being subject to reference pricing. The G-BA can also put time limits on its resolutions, to conduct subsequent assessments based on newer/more mature evidence. This research aims to systematically analyze all time-limited G-BA resolutions.

Authors: Macaulay R, Majeed B, PAREXEL International, London, United Kingdom

To find out more about this poster you can register to download it here after the ISPOR event.

 

Previous Article
Towards Personalization: How Can Advanced Quantitative Methods Help Regulators, Reimbursement Agencies And Clinicians Make Better Decisions
Towards Personalization: How Can Advanced Quantitative Methods Help Regulators, Reimbursement Agencies And Clinicians Make Better Decisions

Next Article
Moving From The Regulator To The Payer And Prescriber
Moving From The Regulator To The Payer And Prescriber